Granted Patent
B2
US 12,398,415 · App. 18/223,835 · Granted Aug 26, 2025
Methods and compositions for assessing and treating intraocular diseases and disorders
Assignee:
SMILEBIOTEK ZHUHAI LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are compositions, devices and systems, methods for assessing, treating and/or preventing an intraocular disease or disorder in a subject, wherein the etiology of the intraocular disease or disorder comprises infection of a microorganism in the intraocular space or cavity of the subject. Provided are compositions, devices and systems, and methods for assessing, treating and/or preventing age-related macular degeneration (AMD) in a subject, e.g., a human patient.
Claims (17)
1. A method for assessing age-related macular degeneration (AMD) in a subject, which method comprises assessing the presence, absence, quantity and/or infectious status of Bacillus megaterium in an intraocular space, cavity or sample of a subject, wherein the etiology of said AMD comprises infection of said Bacillus megaterium in said intraocular space or cavity of said subject.
2. The method of claim 1 , which comprises assessing the presence or absence of the Bacillus megaterium in the intraocular space, cavity or sample for assessing AMD in a subject.
3. The method of claim 1 , which comprises assessing the quantity of the Bacillus megaterium in the intraocular space, cavity or sample for assessing AMD in a subject.
4. The method of claim 1 , which comprises assessing infectious status of the Bacillus megaterium in the intraocular space, cavity or sample for assessing AMD in a subject.
5. The method of claim 1 , wherein the presence, absence, quantity, and/or the infectious status of Bacillus megaterium in the intraocular space, cavity or sample is assessed using a binding assay.
6. The method of claim 1 , wherein the presence, absence, quantity, and/or the infectious status of Bacillus megaterium in the intraocular space, cavity or sample is assessed using a molecular assay.
7. The method of claim 6 , wherein the molecular assay comprises sequencing analysis and/or PCR analysis.
8. The method of claim 1 , which comprises assessing the presence, absence, quantity, and/or the infectious status of Bacillus megaterium using a sample isolated from an intraocular space or cavity of a subject.
9. The method of claim 8 , wherein the sample is isolated from aqueous humor in anterior chamber, a suspensory ligament, ciliary body, ciliary body and muscle, vitreous humor in posterior chamber, retina, choroid, optic nerve, lens, or iris of the subject.
10. The method of claim 1 , wherein the subject is a human.
11. The method of claim 5 , wherein the binding assay is an immunoassay.
12. The method of claim 1 , which comprises assessing the presence, absence, and/or quantity, of Bacillus megaterium in an intraocular space or cavity of a subject.
13. The method of claim 1 , which comprises assessing the infectious status of Bacillus megaterium in an intraocular space or cavity of a subject.
14. The method of claim 1 , which comprises assessing live Bacillus megaterium for assessing AMD in the subject.
15. The method of claim 1 , which further comprises assessing activation of complement system and/or induction of inflammation in the intraocular space, cavity or sample of a subject for assessing AMD in the subject.
16. The method of claim 1 , which is used for risk assessment, diagnosis, prognosis, stratification and/or treatment monitoring of AMD in a subject.
17. The method of claim 1 , which further comprises treating AMD in a subject.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 9, 2023
From: WEI, LAI
To: SMILEBIOTEK ZHUHAI LIMITED
Reel/Frame 065515/0057 →
Priority Claims (1)
CN 201711017087.3
· Oct 26, 2017
· national
Continuity (2)
Division
16758365
References Cited (85)
US 7169555B2
· Stuber
· 2007
[cited by applicant]
US 20100255474A1
· Russwurm et al.
· 2010
[cited by applicant]
CN 1602207A
· 2005
[cited by applicant]
CN 101041864A
· 2007
[cited by applicant]
CN 103045761A
· 2013
[cited by applicant]
CN 106834548A
· 2017
[cited by applicant]
WO 0040262A1
· 2000
[cited by applicant]
WO 02085248A2
· 2002
[cited by applicant]
WO 02092853A1
· 2002
[cited by applicant]
WO WO2013003620A2
· 2013
[cited by examiner]
WO 2015023596A1
· 2015
[cited by applicant]
WO 2016196367A1
· 2016
[cited by applicant]
Bijsterveld et al. 1965 (Bacillus Infections of the Cornea; Arch Ophthal 74: 91-95). (Year: 1965).
[cited by examiner]
Bispo et al. (Detection and Gram Discrimination of Bacterial Pathogens from Aqueous and Vitreous Humor using Real-Time PCR Assays; Investigative Ophthalmology & Visual Science, 52(2):873) (Year: 2011).
[cited by examiner]
1st Office Action for Canadian patent application CA3 080 260, dated Apr. 26, 2021, 6 pages.
[cited by applicant]
Response to 1st Office Action for Canadian patent application CA3 080 260, dated Aug. 26, 2021, 6 pages.
[cited by applicant]
1st Office Action for Chinese patent application CN201711017087.3, dated Jun. 18, 2021, 10 pages.
[cited by applicant]
Response to 1st Office Action for Chinese patent application CN201711017087.3, dated Jun. 18, 2021????, 4 pages.
[cited by applicant]
European Search Report for European patent application EP18869530.8, dated Jun. 30, 2021, 23 pages.
[cited by applicant]
Response to European Search Report for European patent application EP18869530.8, dated Jan. 18, 2022, 3 pages.
[cited by applicant]
1st Office Action for Japanese patent application JP2020-543679, dated Jun. 1, 2021, 7 pages.
[cited by applicant]
Response to 1st Office Action for Japanese patent application JP2020-543679, dated Jul. 21, 2021, 9 pages.
[cited by applicant]
International Search Report for International patent application for PCT/CN2018/112022 (WO2019080916), dated May 2, 2019, 7 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International patent application for PCT/CN2018/112022 (WO2019080916), dated May 2, 2019, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability for International patent application for PCT/CN2018/112022 (WO2019080916), dated Apr. 28, 2020, 6 pages.
[cited by applicant]
Bui et al., “Single-Digit Pathogen and Attomolar Detection with the Naked Eye Using Liposome-Amplified Plasmonic Immunoassay,” Nano Letters, vol. 15 , No. 9, Aug. 26, 2015 , p. 6239-6246 Doi:10.1021/acs.nanolett.5b02837.
[cited by applicant]
Gilger et al., “Role of bacteria in the pathogenesis of recurrent uveitis in horses from the southeastern United States,” Am J Vet Res, 2008, vol. 69, No. 10, p. 1329-1335.
[cited by applicant]
Gündüz et al., “Conjunctival flora in Behçet patients,” Canadian Journal of Ophthalmology, Aug. 1, 2008, vol. 43, No. 4 , p. 476-479 Doi:10.3129/i08-089.
[cited by applicant]
Han et al., “The study on rapid diagnosis of infective endophthalmitis with polymerase chain reaction combined with direct gene sequencing,” Beijing Medical, vol. 30, No. 7, 2008, p. 418-420 DOI:10.15932/j.0253-9713.200…
[cited by applicant]
Knox et al., “Identification of Bacterial Pathogens in Patients With Endophthalmitis by 16S Ribosomal DNA Typing,” American Journal of Ophthalmology, vol. 128, No. 4, Oct. 1999, p. 511-512.
[cited by applicant]
Liu et al., “Chapter 16 Ocular trauma,” Ophthalmology Foundation and Diagnosis and Treatment Practice, Jul. 31, 2015, p. 295-296.
[cited by applicant]
Meri et al., “Microbes Bind Complement Inhibitor Factor H via a Common Site,” PLOS Pathogens, vol. 9, No. 4,Apr. 2013 , p. e1003308.
[cited by applicant]
Milder et al., “Changes in Antibiotic Resistance Patterns of Conjunctival Flora Due to Repeated Use of Topical Antibiotics after Intravitreal Injection,” Ophthalmology, vol. 119 , No. 7, Jul. 1, 2012, p. 1420-1424 Doi:1…
[cited by applicant]
Okhravi et al., “PCR-Based Evidence of Bacterial Involvement in Eyes with Suspected Intraocular Infection,” Investigative ophthalmology visual science, Oct. 2000, vol. 41, No. 11, p. 3474-3479.
[cited by applicant]
Robman et al., “Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration,” American Journal of Epidemiology, vol. 161 , No. 11, Jan. 1, 2005 , p. 1013-1019 Doi:10.1093/aje/kwi130.
[cited by applicant]
Thanathanee et al., “Conjunctivitis: Systematic Approach to Diagnosis and Therapy,” Current Infectious Disease Reports (2011) 13:141-148 Doi:10.1007/s11908-011-0167-y.
[cited by applicant]
Yang et al., “Identification of pathogenic bacteria in aqueous and vitreous of Endophthalmitis by 16S rDNA sequencing technique,” Chin.J. Exp. Ophthalmol, vol. 34, No. 10, Oct. 2016, p. 883-887 Doi:10.3760/cma.j.issn.20…
[cited by applicant]
Yu et al., “PCR Assay for Detection of Bacillus Licheniformis,” Guangdong Journal of Animal and Veterinary Science, 2015, vol. 40, No. 4, p. 35-37.
[cited by applicant]
Zheng et al., “Microbiome Characterization in Retina and choroid of Patients with Age-related Macular Degeneration,” Investigative Ophthalmology Visual Science, abstract, May 1, 2016, 2 pages.
[cited by applicant]
Bacillus licheniformis strain HRBL-15TD17 chromosome, complete genome, Kim, H.-R., Genbank database, GenBank: CP014781.1, Mar. 22, 2016.
[cited by applicant]
Aarthi et al. 2011 (Identification of bacteria in culture negative and polymerase chain reaction (PCR) positive intraocular specimen from patients with infectious endophthalmitis; J of Microbiological Methods 85: 47-52)…
[cited by applicant]
Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 2011;27:863-4. doi: 10.1093/bioinformatics/btr026. Epub Jan. 28, 2011.
[cited by applicant]
Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 2015;12:357-60. doi: 10.1038/nmeth.3317. Epub Mar. 9, 2015.
[cited by applicant]
Schmieder R, Edwards R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One 2011;6:e17288. doi: 10.1371/journal.pone.0017288.
[cited by applicant]
Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 2014;15:R46. doi: 10.1186/gb-2014-15-3-r46.
[cited by applicant]
Abubucker S, Segata N, Goll J, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol 2012;8:e1002358. doi: 10.1371/journal.pcbi.1002358. Epub Jun. 13, 2012.
[cited by applicant]
Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60. doi: 10.1186/gb-2011-12-6-r60.
[cited by applicant]
Peyman GA, Paque JT, Meisels HI, Bennett TO. Postoperative endophthalmitis: a comparison of methods for treatment and prophlaxis with gentamicin. Ophthalmic Surg 1975;6:45-55 (Abstract).
[cited by applicant]
Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 2002;99:14682-7. Epub Oct. 21, 2002.
[cited by applicant]
Doyle SL, Campbell M, Ozaki E, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 2012;18:791-8. doi: 10.1038/nm.2717.
[cited by applicant]
Wang Y, Hanus JW, Abu-Asab MS, et al. NLRP3 upregulation in retinal pigment epithelium in age-related macular degeneration. Int J Mol Sci 2016;17(1).E73. doi: 10.3390/ijms17010073.
[cited by applicant]
Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17. doi: 10.1056/NEJMra0801537.
[cited by applicant]
Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A review of current and future management of geographic atrophy. Ophthalmol Ther 2017;6:69-77. doi: 10.1007/s40123-017-0086-6. Epub Apr. 8, 2017.
[cited by applicant]
Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 2014;15:151-71.:10.1146/ annurev-genom-090413-…
[cited by applicant]
Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 2016;48:134-43. doi: 10.1038/ng.3448. Epub …
[cited by applicant]
Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013;Apr. 2013;45:433-9.
[cited by applicant]
Forrester JV, Klaska IP, Yu T, Kuffova L. Uveitis in mouse and man. Int Rev Immunol 2013;32:76-96. doi: 10.3109/08830185.2012.747524.
[cited by applicant]
Abubucker S, Segata N, Goll J, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol 2012;8:e1002358. doi: 10.1371/journal.pcbi.. Epub Jun. 13, 2012.
[cited by applicant]
Deramo VA, Ting TD. Treatment of Propionibacterium acnes endophthalmitis. Curr Opin Ophthalmol 2001;12:225-9.
[cited by applicant]
Perry A, Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev Anti Infect Ther 2011;9:1149-56. doi: 10.586/eri.11.137.
[cited by applicant]
Franzosa EA, Hsu T, Sirota-Madi A, et al. Sequencing and beyond: integrating molecular ‘omics’ for microbial community profiling. Nat Rev Microbiol 2015;13:360-72. doi: 10.1038/nrmicro3451. Epub Apr. 27, 2015.
[cited by applicant]
Kugadas A, Gadjeva M. Impact of microbiome on ocular health. Ocul Surf 2016;14:342-9. doi: 10.1016/j.jtos.2016.04.004. Epub May 14.
[cited by applicant]
St Leger AJ, Desai JV, Drummond RA, et al. An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal gammadelta T cells. Immunity 2017;47:148-58.e5. doi: 10.1016/j.immuni.…
[cited by applicant]
Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol 1987;5:21-42.
[cited by applicant]
Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular d…
[cited by applicant]
Kumar DK, Choi SH, Washicosky KJ, et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci Transl Med 2016;8:340ra72. doi: 10.1126/scitranslmed.aaf059.
[cited by applicant]
Singh B, Su YC, Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 2010;78:545-60. doi: 10.1111/j.365-2958.010.07373.x. Epub Sep. 27, 2010.
[cited by applicant]
Kattan OM, Kasravi FB, Elford EL, Schell MT, Harris HW. Apolipoprotein E-mediated immune regulation in sepsis. J Immunol 2008;181:1399-408.
[cited by applicant]
Khan KN, Mahroo OA, Khan RS, et al. Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin…
[cited by applicant]
Mattapallil MJ, Caspi RR. Compliments of factor H: What's in it for AMD? Immunity 2017;46:167-9. doi: 10.1016/j.immuni.2017.02.008.
[cited by applicant]
Friedrich U, Datta S, Schubert T, et al. Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-beta signaling. Hum Mol Genet 2015;24:6361-73. doi: 10.1093/hmg/ddv346. Epub Aug…
[cited by applicant]
Morrison MA, Magalhaes TR, Ramke J, et al. Ancestry of the Timorese: age-related macular degeneration associated genotype and allele sharing among human populations from throughout the world. Front Genet 2015;6:238.:10.…
[cited by applicant]
Yang et al. 2016 (Identification of pathogenic bacteria in aqueous and vitreous of endophthalmitis by 16S rDNA sequencing technique; Chin. J. Exp. Ophtalmol. 34(1): 885-886 (Year: 2016).
[cited by applicant]
Carroll et al. 2000 (Detection of and Discrimination between Gram-Positive and Gram-Negative Bacteria in Intraocular Samples by Using Nested PCR; Journal of Clinical Microbiology 38(5):1753-1757) (Year: 2000).
[cited by applicant]
U.S. Appl. No. 16/758,365, Restriction Requirement dated May 17, 2022.
[cited by applicant]
U.S. Appl. No. 16/758,365, Response to Restriction Requirement dated Jul. 14, 2022.
[cited by applicant]
U.S. Appl. No. 16/758,365, Nonfinal Office action dated Aug. 26, 2022.
[cited by applicant]
U.S. Appl. No. 16/758,365, Response to Nonfinal Office action dated Nov. 18, 2022.
[cited by applicant]
U.S. Appl. No. 16/758,365, Final Office action dated Jan. 12, 2023.
[cited by applicant]
U.S. Appl. No. 16/758,365, Response to Final Office action dated Apr. 11, 2023.
[cited by applicant]
U.S. Appl. No. 16/758,365, Notice of Allowance dated Apr. 21, 2023.
[cited by applicant]
U.S. Appl. No. 16/758,365, Amendment Under 37 CFR 1.312 dated Jul. 18, 2023.
[cited by applicant]
U.S. Appl. No. 16/758,365, Issue Notification dated Aug. 16, 2023.
[cited by applicant]